Skip to content
Back to meeting Original
Roberto Ferrara· @RobertoFerrara_ · X·· 4 days agoScore70

lorlatinib

Body

Still 17% of ALK+ patients with long term response from lorlatinib have a TP53 mut.
Interesting to know functional classification of TP53 mut in disruptive or not disruptive to understand the impact of function rather than mutation itself on treatment outcome #ESMO2026

35 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
2636ROmatched by Rapid oral 1: NSCLC, metastatic

Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study

https://esmocongress.esmo.org

Source: Roberto Ferrara · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.